Patients with refractory CMV infection following allo-HSCT are at high risk for CMV disease and non-relapse mortality
Jun Kong,Ying Jun Chang,Huan Chen,Yu Hong Chen,Wei Han,Yu Wang,Chen Hua Yan,Jing Zhi Wang,Feng Rong Wang,Chen Yao,Xiao Hui Zhang,Lan Ping Xu,Kai Yan Liu,Xiao Jun Huang
2015-01-01
Abstract:word count: 228 17 Text word count: 2497 18 Number of tables: 5 19 Number of figures: 3 20 Number of supplement tables: 2 21 22 23 24 25 M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT 2 1 Abstract 2 The preemptive therapy is an effective approach for CMV control; however, refractory CMV still 3 occurred in a considerable group of recipients post allogeneic hematopoietic stem cell 4 transplantation (allo-HSCT). Until now, hardly any data have been available about the clinical 5 characteristics and risk factors of refractory CMV, nor its’ potential harmful impact on the clinical 6 outcome following allo-HSCT. We studied transplant factors affecting refractory CMV in the +100 7 days post allo-HSCT and the impact of refractory CMV on the risk of CMV disease and non-relapse 8 mortality (NRM). We retrospectively studied 488 consecutive patients with CMV infection post 9 allo-HSCT. Patients with refractory CMV in the +100 days post allo-HSCT had a higher incidence of 10 CMV disease and NRM than did those without refractory CMV (11.9% vs. 0.8% and 17.1% vs. 11 8.3%, respectively). Multivariate analysis showed that refractory CMV infection in the +100 days 12 post allo-HSCT was an independent risk factor for CMV disease (HR=10.539, 95% CI 2.467-45.015, 13 p=0.001) and that during the +60-+100 days was an independent risk factor of NRM (HR=8.435, 14 95% CI 1.511-47.099, p=0.015). Clinical factors impacting the risk of refractory CMV included 15 receiving transplantation from HLA-mismatched family donors (HR=2.012, 95% CI 1.603-2.546, 16 p<0.001), as well as acute GVHD (HR=1.905, 95% CI 1.352-2.686, p<0.001). We conclude that 17 patients with refractory CMV during the early stage post allo-HSCT were at a high risk of both 18 CMV disease and NRM. 19 20 M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT 3 Introduction 1 Viral infections remain important causes of morbidity and mortality after allogeneic 2 hematopoietic stem cell transplantation (allo-HSCT), especially cytomegalovirus (CMV) infection. 3 A preemptive therapy approach enabled almost complete prevention of CMV disease; however, 4 refractory CMV still developed in a subgroup of patients after allo-HSCT. [1-6] Refractory CMV, 5 which was defined as CMV infection persisting over 2 weeks in spite of standard antivirus therapy, 6 occurred in more than 40% of recipients post allo-HSCT, leading to a prolonged medication 7 treatment time.[1, 5, 7] Until now, hardly any data have been available about the clinical 8 characteristics and risk factors of refractory CMV infection, or regarding its potential harmful 9 impact on the clinical outcome after allo-HSCT. It has been well documented that clinical factors 10 such as acute graft versus host disease (aGVHD), donor/recipient serostatus, and receiving a graft 11 from an unrelated donors are risk factors for CMV infection following allo-HSCT [2, 8-11]. 12 Whether these clinical factors have an impact on the refractory CMV is unknown. Almyroudis et 13 al. [6] demonstrated that persistent CMV reactivation occurred in 39% of T-cell-depleted HSCT 14 despite treatment with currently available antivirals and the maximum CMV level was associated 15 with persistent CMV reactivation. Ljungman et al. [8] demonstrated that the viral load kinetics 16 after initiation of antiviral therapy was predictive of the risk of developing CMV disease, and that 17 the patients whose viral load decreased slower in the first week had a higher risk of CMV disease 18 in a group of 162 patients. Beyond that, scarcely any data are available about the relationship 19 between refractory CMV and CMV disease or mortality. Therefore, we performed a retrospective 20 study to analyze the clinical characteristics and risk factors of refractory CMV, as well as the 21 effects of refractory CMV on the risk of CMV disease and mortality in a series of consecutive 22 allo-HSCT recipients. 23 M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT